Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized study of HZ-H08905 versus chidamide in relapsed or refractory peripheral T-cell lymphoma
ChiCTR2500098784Phase 3Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HZ-H08905 and tucidinostat in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Progression-free survival and Patient-reported quality of life evaluation. Started Mar 2025; status: recruiting.
02
Drugs
HZ-H08905tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2500098784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098784.